1,246 results on '"Koschmieder, Steffen"'
Search Results
52. The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling
53. Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia
54. JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms
55. Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study
56. Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms
57. Transcriptional alteration of DNA repair genes in Philadelphia chromosome negative myeloproliferative neoplasms
58. Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor
59. Telemedizin in der Hämatologie und Onkologie
60. Targeted DNA Methylation Analysis Facilitates Leukocyte Counts in Dried Blood Samples
61. Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms
62. P1004: ACTIVATING MUTATIONS IN JAK2 AND CALR DIFFERENTIALLY AFFECT INTRACELLULAR CALCIUM LEVELS AND CALCIUM FLUX
63. P988: MUTANT CALRETICULIN AND JAK2V617F DRIVER MUTATIONS INDUCE DISTINCT MITOTIC DEFECTS IN MYELOPROLIFERATIVE NEOPLASMS
64. P1008: THE TELOMERASE INHIBITOR IMETELSTAT DIFFERENTIALLY TARGETS JAK2V617F- VERSUS CALR-MUTANT MYELOPROLIFERATIVE NEOPLASM CELLS AND INHIBITS JAK-STAT SIGNALING
65. PB2195: CHARACTERISTICS OF PATIENTS WITH POLYCYTHEMIA VERA: RESULTS FROM A US ELECTRONIC HEALTH RECORDS DATABASE.
66. Dexamethasone nanomedicines for COVID-19
67. Tyrosine kinase inhibitor–induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors
68. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
69. Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms
70. Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling
71. Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML)
72. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation
73. Biobankinganforderungen aus Sicht des Klinikers: Erfahrungen aus der Hämatologie und Onkologie
74. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms
75. Kapitel 31 - Ph-negative myeloproliferative Neoplasien
76. Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group
77. The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues
78. Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET
79. Identification of Adult Patients With Classical Dyskeratosis Congenita or Cryptic Telomere Biology Disorder by Telomere Length Screening Using Age-modified Criteria
80. Data from Type I but Not Type II Calreticulin Mutations Activate the IRE1α/XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms
81. Supplementary Data from Type I but Not Type II Calreticulin Mutations Activate the IRE1α/XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms
82. Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms.
83. Mutant NRAS Q61K is responsible for MAPK pathway activation in the MARIMO cell line and renders these cells independent of the CALR–MPL–JAK2–STAT5 pathway
84. Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita
85. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
86. Supplementary Tables S1-S7 from Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients
87. Supplementary Figures S1-S16 from Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients
88. Revised supplementary file from Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor–Sensitive and -Resistant Chronic Myeloid Leukemia
89. Data from Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients
90. Supplementary Figure S2 from JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms
91. Supplementary Figure Legend from JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms
92. Supplementary Table 1 from DNA Methylation of Tumor Suppressor Genes in Clinical Remission Predicts the Relapse Risk in Acute Myeloid Leukemia
93. Supplementary Table 2 from DNA Methylation of Tumor Suppressor Genes in Clinical Remission Predicts the Relapse Risk in Acute Myeloid Leukemia
94. KIT D816V Mast Cells Derived from Induced Pluripotent Stem Cells Recapitulate Systemic Mastocytosis Transcriptional Profile
95. Non-Canonical Hedgehog Signaling Mediates Profibrotic Hematopoiesis-Stroma Crosstalk in Myeloproliferative Neoplasms
96. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
97. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey
98. Additional file 1 of Quantification of hematopoietic stem and progenitor cells by targeted DNA methylation analysis
99. Bosutinib: A Novel Second-Generation Tyrosine Kinase Inhibitor
100. Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.